Vessl Overview
- Year Founded
-
2000
- Status
-
Out of Business
- Employees
-
3
- Latest Deal Type
-
Out of Business
Vessl General Information
Description
Developer of gene and cell therapy products designed to treat patients who suffer from cardiovascular and other vascular-related conditions. The company's products are used in therapies for patients with peripheral artery disease, coronary artery disease, and renal disease requiring hemodialysis, enabling healthcare providers to treat and address heart and blood vessel disorders
Contact Information
Website
www.vessltherapy.comCorporate Office
- Colab Square Facility
- 6 HaYozma Street
- Yokne'am Illit 2069203
- Israel
Corporate Office
- Colab Square Facility
- 6 HaYozma Street
- Yokne'am Illit 2069203
- Israel
Vessl Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Out of Business | 29-May-2026 | Completed | Out of Business | |||
| 6. Later Stage VC | 25-Apr-2021 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 01-Jan-2012 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 27-Oct-2009 | Completed | Generating Revenue | |||
| 3. Debt - General | 01-Jan-2009 | Completed | Generating Revenue | |||
| 2. Later Stage VC | 31-Dec-2006 | $6M | $10M | Completed | Generating Revenue | |
| 1. Early Stage VC | 23-May-2004 | $4M | $4M | Completed | Startup |
Vessl Patents
Vessl Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3995569-A1 | Methods of preconditioning vascular cells for transduction, methods of transduction and methods of preserving transduced cells | Inactive | 10-Nov-2020 | ||
| US-12698477-B2 | Methods of preconditioning vascular cells for transduction, methods of transduction and methods of preserving transduced cells | Active | 10-Nov-2020 | ||
| US-20220145258-A1 | Methods of preconditioning vascular cells for transduction, methods of transduction and methods of preserving transduced cells | Active | 10-Nov-2020 | ||
| EP-3226886-A1 | Use of fibulin-5 for the treatment of keloid scars | Inactive | 07-Dec-2014 | ||
| EP-3226886-A4 | Use of fibulin-5 for the treatment of keloid scars | Inactive | 07-Dec-2014 | A61K38/1741 |
Vessl Signals
Vessl FAQs
-
When was Vessl founded?
Vessl was founded in 2000.
-
Where is Vessl headquartered?
Vessl is headquartered in Yokne'am Illit, Israel.
-
What is the size of Vessl?
Vessl has 3 total employees.
-
What industry is Vessl in?
Vessl’s primary industry is Drug Discovery.
-
Is Vessl a private or public company?
Vessl is a Private company.
-
What is Vessl’s current revenue?
The current revenue for Vessl is .
-
How much funding has Vessl raised over time?
Vessl has raised $48.5M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process